| Literature DB >> 34959705 |
Mohamed A A Orabi1, Heba M A Khalil2, Mohamed E Abouelela3, Dalia Zaafar4, Yasmine H Ahmed5, Reham A Naggar6, Hamad S Alyami7, El-Shaymaa Abdel-Sattar8, Katsuyoshi Matsunami9, Dalia I Hamdan10.
Abstract
Chemotherapeutic-related toxicity exacerbates the increasing death rate among cancer patients, necessitating greater efforts to find a speedy solution. An in vivo assessment of the protective effect of the C. macrocarpa leaves polar fraction of hydromethanolic extract against doxorubicin (Dox)-induced neurotoxicity was performed. Intriguingly, this fraction ameliorated Dox-induced cognitive dysfunction; reduced serum ROS and brain TNF-α levels, upregulated the brain nerve growth factor (NGF) levels, markedly reduced caspase-3 immunoexpression, and restored the histological architecture of the brain hippocampus. The in vivo study results were corroborated with a UPLC-ESI-MS/MS profiling that revealed the presence of a high percentage of the plant polyphenolics. Molecular modeling of several identified molecules in this fraction demonstrated a strong binding affinity of flavan-3-ol derivatives with TACE enzymes, in agreement with the experimental in vivo neuroprotective activity. In conclusion, the C. macrocarpa leaves polar fraction possesses neuroprotective activity that could have a promising role in ameliorating chemotherapeutic-induced side effects.Entities:
Keywords: Carissa macrocarpa; UPLC-ESI-MS/MS; cytotoxicity; doxorubicin; molecular docking; neurotoxicity
Year: 2021 PMID: 34959705 PMCID: PMC8709457 DOI: 10.3390/ph14121305
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Figure 1Effect of Dox with or without different doses of C. macrocarpa leaves polar fraction on the cognitive functions of rats. (a) Y-maze: Number of arm entries, (b) Y-maze: Spontaneous alternation percentage, (c) Novel object recognition test: Total exploration time, and (d) Novel object recognition test: Preference for new object. Data are expressed as mean ± SEM, one-way ANOVA followed by post-hoc test Tukey test for seven rats in each group. * Significant from control group, $ Significant from Dox group, @ Significant from Dox+ C.100 group, and # Significant from Dox+ C.300 group, p < 0.05.
Figure 2Effect of Dox with or without different doses of C. macrocarpa leaves polar fraction on the brain levels of ROS, NGF, and TNF-α. (a) Reactive oxygen species, (b) Nerve growth factor, and (c) Tumor necrosis factor-alpha. Data are expressed as mean ± SEM, one-way ANOVA followed by post hoc Tukey test for seven rats in each group. * Significant from control group, $ Significant from Dox group, @ Significant from Dox+ C.100 group, and # Significant from Dox+ C.300 group, p < 0.05.
Figure 3Brain tissue sections of albino rats from the hippocampal region H and E ×400. (a) Control rats (Group Ⅰ) showed normal molecular layer (M), pyramidal cell layer (P), polymorphic cell layer (PL). The molecular layer contained neuronal cells (yellow arrow) and neuroglia cells (red arrow). The pyramidal layer consisted of triangular cells (chevron), and the polymorphic cell layer contained neuronal cells (yellow arrow) and neuroglia (red arrow). (b) Dox-exposed rats (Group Ⅱ) revealed histopathological changes such as neuropil vacuolation (circle), pyknotic neuroglia cells (red arrow), degenerated, shrunken and hyperchromatic pyramidal cell (yellow arrow). A wide perivascular space with congested blood capillary (yellow chevron) was observed. Additionally, some pyramidal cells with neurofibrillary tangles (line arrow) and pericellular space (red chevron). (c) Dox+ C100 treated rats (Group Ⅲ) revealed partial recovery compared to group Ⅱ in the form of diminishing of neuropil vacuolation (circle), perivascular space (yellow chevron), and perineuronal space (green chevron). Pyramidal cells restored their triangular shape with a vesicular nucleus (yellow arrow), but few pyramidal cells appeared degenerated (red arrow). (d) Dox+ C300 (Group Ⅳ) and (e) Dox+ C500 (Group Ⅴ) treated rats showed regeneration signs same to group Ⅲ in the form of nearly normal pyramidal cells (red arrow), few neuropil vacuolations (yellow arrow and circle), and reduced perivascular space (yellow chevron).
Figure 4Immunohistochemically caspase-3-stained hippocampus sections (×400). (a) Control rats (Group Ⅰ) showing negligible immunoreactivity to caspase-3 (arrow). (b) Dox-exposed group (Group Ⅱ) showing strong immunoexpression to caspase-3 (arrow). (c) Mild immunoreactivity to caspase-3 (arrow) in Dox+ C.100 administered rats (Group Ⅲ). (d) Dox+ C.300 (Group Ⅳ) and (e) Dox+ C.500 (Group Ⅴ) treated rats showing negligible immune reaction (arrow). (f) A bar graph showing a significant increase in the area% covered by Caspase3-positive immunoreactive cells within the hippocampus in Dox-exposed albino rats (Group Ⅱ) compared to the control rats (Group Ⅰ) and a significant decrease in Dox + C. macrocarpa treated rats (Groups Ⅲ, Ⅳ, and Ⅴ) compared to Dox-exposed rats. Data are presented as mean values ± SEM, one-way ANOVA followed by post hoc test Tukey test for seven rats in each group. * Significant from control group, $ Significant from Dox group, @ Significant from Dox+ C.100 group, and # Significant from Dox+ C.300 group, p < 0.05.
Secondary metabolites identified in the C. macrocarpa leaves polar fraction using UPLC-ESI-MS-MS.
| Peak No. | Rt | [M−H]− | [M+H]+ | MS2 | Tentative Identification | References |
|---|---|---|---|---|---|---|
| 1 | 0.74 | 377.16 | 379.25 | 333, 271, 257, 163, 119 | Carinol | [ |
| 2 | 1.87 | 353.16 | 355.13 | 191,179,161 | 3-O-Caffeolyquinic acid | [ |
| 3 | 2.03 | 353.17 | - | 191,173,161 | 4-O-Caffeolyquinic acid | |
| 4 | 2.13 | 325.14 | - | 187, 163, 145 | Coumaroyl- | [ |
| 5 | 2.161 | 353.20 | - | 191,179,161 | 5-O-Caffeolyquinic acid | [ |
| 6 | 2.24 | 577.27 | - | 425, 289 | Type B (epi)catechin dimer | [ |
| 7 | 2.45 | 865.50 | - | 451, 425, 407, 289 | Type B (epi)catechin trimer | |
| 8 | 2.85 | 319.17 | - | 301, 275, 257, 231, 203,163, 119 | 5-O- | [ |
| 9 | 2.87 | - | 343.18 | 326, 311, 285 | Caffeic acid 3-glucoside | [ |
| 10 | 2.87 | 451.30 | - | 408, 393, 351, 337, 301, 273, 245 | Catechin-3-O-glucoside | [ |
| 11 | 2.87 | 319.17 | - | 275, 257, 199, 163, 119 | 4-O- | [ |
| 12 | 2.87 | 451.31 | - | 391, 343, 301, 287, 273, 247 | Epicatechin-3-O-glucoside | [ |
| 13 | 3.00 | 289.09 | - | 245, 205, 203, 187, 179, 161 | (epi) Catechin | [ |
| 14 | 5.05 | 755.44 | - | 593, 285 | Kaempferol-7-O-hexoside-3-O-rutinoside | [ |
| 15 | 5.12 | 755.52 | - | 609, 301 | Quercetin-7-O-deoxyhexoside-3-O-deoxyhexosyl-hexoside | |
| 16 | 5.14 | 451.37 | - | 391, 343, 301, 287, 273, 247 | Epicatechin-3-O-glucoside isomer | [ |
| 17 | 5.52 | 739.40 | - | 593, 285 | Kaempferol-7-O -deoxyhexoside-3-O -deoxyhexosyl-hexoside isomer 1 | [ |
| 18 | 5.59 | 739.42 | - | 593, 285 | Kaempferol-7-O-deoxyhexoside-3-O-deoxyhexosyl-hexoside isomer 2 | |
| 19 | 5.59 | 609.27 | - | 301 | Quercetin-3-O-deoxyhexosyl-hexoside isomer 1 | |
| 20 | 5.75 | 609.33 | 611.29 | 465, 303 | Quercetin-3-O-deoxyhexosyl-hexoside isomer 2 | |
| 21 | 5.80 | 577.29 | - | 425, 289 | Type B (epi)catechin dimer | |
| 22 | 5.90 | 449.17 | - | 317, 316 | Myricetin-3-O-xyloside | [ |
| 23 | 6.04 | - | 302.89 | 275, 257, 229, 215, 153 | Quercetin | |
| 24 | 6.13 | 593.33 | - | 557, 467, 441, 425, 407, 289 | (epi) Gallocatechin-(epi)catechin | [ |
| 25 | 6.58 | 515.30 | - | 353, 179 | Dicaffeoylquinic acid | [ |
| 26 | 6.80 | 136.94 | - | 109, 93 | Hydroxy benzoic acid | [ |
| 27 | 7.01 | 593.33 | - | 557, 467, 441, 425, 407, 289 | (epi) gallocatechin-(epi)catechin | [ |
| 28 | 8.12 | 196.93 | - | 120, 104, 93, 87 | Syringic acid | [ |
| 29 | 9.14 | 573.70 | - | 397, 223, 173 | Feruloyl-O-sinapoylquinic acid | [ |
| 30 | 9.94 | 939.06 | - | 778, 735, 732, 717, 571 | Diacetoxy-5-methoxyphenyl) acroyl-O- | [ |
| 31 | 13.26 | 577.48 | - | 425, 289 | (epi) Catechin dimer | [ |
| 32 | 13.30 | 543.56 | - | 353, 173 | Dimethoxycinnamoyl-O-caffeoylquinic acid | [ |
| 33 | 15.66 | 543.33 | - | 353, 173 | Dimethoxycinnamoyl-O-caffeoylquinic acid isomer | |
| 34 | 16.52 | 352.99 | - | 179,161 | 3-O-Caffeoylshikimic acid | |
| 35 | 16.59 | - | 383.25 | 369, 351, 195 | Dimethoxycinnamoylquinic acid | |
| 36 | 18.58 | 455.47 | - | 439, 419, 411, 410, 407, 397 | Ursolic acid | [ |
| 37 | 19.06 | 455.46 | - | 439, 419, 411, 410, 407, 397 | Carissic acid (isomer of ursolic acid) | |
| 38 | 19.16 | 455.50 | 457.43 | 439, 419, 411, 410, 407, 397 | Oleanolic acid | |
| 39 | 25.30 | - | 413.31 | 395, 256, 214 | Stigmasterol | [ |
| 40 | 27.02 | - | 465.45 | 301, 300, 257, 255, 229, 179. 151 | Hyperoside | [ |
| 41 | 27.21 | - | 465.42 | 301, 300, 257, 255, 229, 179. 151 | Isoquercetin | |
| 42 | 27.31 | 621.68 | - | 501 | 2(R)-26-([(2E)-3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2- propen-1-yl]oxy)-2,3-dihydroxypropyl ester | [ |
| 43 | 31.25 | 429. 31 | 430.92 | 205, 191, 177, 149, 121 | α-Tocopherol |
Figure 52D (a) and 3D (b) interactions complex of procyanidin B6 with TACE (PDB ID: 2FV5).